SALT LAKE CITY and TORONTO, November 3, 2014 (PRNewswire/-) EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules announces a poster presentation of its proprietary intraoral lorazepam spray at the American Association of Pharmaceutical Scientists (AAPS) Conference.
The AAPS conference is held at the San Diego Convention Center until November 6, 2014 in San Diego, California.
The abstract entitled “Lorazepam Oral Spray for Epileptic Emergency Treatment” (Poster # M1204) will be presented by the company’s Chief Medical Officer Dr. Michael Weisspapir and the company’s Chief Scientific Officer, Dr. Joseph Schwarz on Monday, November 3rd. The session time for the poster presentation is between 1:30 p.m. – 5:00 p.m. at the San Diego Convention Center Halls B-F.
The poster authored by Drs. Joseph Schwarz, Michael Weisspapir, Peter Carlen present the results of an animal study utilizing the company’s intraoral transmucosal Lorazepam, in a proprietary self-nanoemulsifying drug delivery (SNEDDS). Lorazepam SNEDDS, administered to mice intraorally 3 or 5 minutes before the start of a PTZ infusion showed anticonvulsant efficacy comparable to parenteral administration of Lorazepam injectable solution. The conclusions of the study was that a Lorazepam intraoral spray may be a safe, convenient and rapid acting formulation that can be developed and applied for both hospital and out-of-hospital settings. A high drug loading – 0.5 mg of Lorazepam in a single actuation (50 microliters) allows for easy and effective dose adjustment. The Lorazepam intraoral spray development is likely to satisfy requirement for a 505 (b)(2) regulatory pathway in the USA or the hybrid pathway in Europe.
The intraoral Lorazepam Spray provides a non-invasive method for the treatment of acute and repetitive seizures. This spray delivers a low volume, oral anti-convulsant formulation designed to be a quick and effective treatment of acute seizures in hospital, home or ambulatory settings. This oral spray of the potent anticonvulsant is an exceptionally convenient alternative to injectable benzodiazepines that efficiently control epilepsy emergencies. The intraoral spray formulation can be used by the patient, paramedics, or any other available non-trained persons, even during the ongoing seizures.
“We are pleased to have the opportunity to present our innovative intraoral Lorazepam Spray at the AAPS conference”, says Anna Gluskin, EastGate’s CEO. “Lorazepam is a well-known drug and our very own sub-micron self-nanoemulsifying drug delivery platform will make this a safe, effective and easy-accessible treatment for epileptic patients, both adults and children.” “The company anticipates that it will pursue the 505(b)(2) regulatory pathway in order to expedite this development”, says Gluskin.
About EastGate Acquisitions Corporation
EastGate Acquisitions Corporation is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated usefulness in improvement of bioavailability and biological action of incorporated molecules. The Company’s product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions. EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate’s approach will be most beneficial for patient care. For more information, please visit the company’s website atwww.EastGatePharmaceuticals.com.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652
Text: ESAQ to 87804